Paul M. Silva
Paul M. Silva has made 1 open-market purchase worth $100k since Oct 22, 2026, in 1 company. The latest: $100k of RAPP, filed Oct 22, 2026, scored 62 out of 100.
Director, Rapport Therapeutics, Inc.
Follow Paul M. Silva, freeOpen the live feed
A free account gets an alert the minute a new buy or sale is filed.
Purchases
| Filed | Stock | Stake | Score | Bought | 1 week | 1 month |
|---|---|---|---|---|---|---|
| Oct 22 Form 4 (opens sec.gov) |
RAPPRapport Therapeutics, Inc. · DirectorDirector · 5 insiders buying · Near 52-week low | New position | 62 | $100k 3,680 at $27.07 |
−3.4% | waiting |
Track record (hypothetical): a week after the filing, these buys averaged −3.4% (0% up, 1 measured).
Questions
What stock has Paul M. Silva bought?
RAPP (Rapport Therapeutics, Inc.), all on the open market and reported on SEC Form 4.
When did Paul M. Silva last buy?
Oct 22, 2026: 3,680 shares of RAPP at $27.07, $100k in all (Form 4 (opens sec.gov)).
Has Paul M. Silva filed a notice of a planned sale?
Not in the filings on record. A Form 144 is the notice an insider must file before selling restricted or control shares, and it lands on EDGAR before the sale is reported.
Is Paul M. Silva a routine or an opportunistic buyer?
There isn't enough history to say yet.
Data as of Oct 22, 2026, from SEC EDGAR Form 4 filings: open-market purchases (code P) of $25,000 or more, and open-market sales. Every row links to its filing. Scores summarise what a filing says (how the score works); outcomes are hypothetical, from the first close after the filing, and past results don't predict future ones. Disclaimer